Lilly (LLY) Completes Acquisition of Morphic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- AI warnings knock Nasdaq futures, pressure tech stocks
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% amid Saudi pipeline outage after attack
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Oracle raises full year profit guidance, stock rises after hours
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
August 16, 2024 8:39 AM EDTBroadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057
Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology
INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of... More
